New heart drug acoramidis tested in Real-World setting

NCT ID NCT07235462

Recruiting now Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This observational study follows up to 2,000 adults with ATTR-CM, a serious heart condition, who are starting treatment with acoramidis as part of their normal care. Researchers will track patient characteristics, how the drug is used, and its effects on heart function and quality of life. The goal is to gather real-world evidence on acoramidis to improve management of this progressive disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Acoramidis (brand name BEYONTTRA)
What this could lead to: If successful, this study will show how well acoramidis works in everyday medical practice, helping doctors better manage ATTR-CM and improve patient care.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. It only includes patients already prescribed acoramidis, which may limit generalizability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiomyopathy familial amyloid neuropathy heart failure wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)

Contacts and locations

Locations

Universitaetsklinik Heidelberg
RECRUITING

Heidelberg, 69120, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.